Brevan Howard Capital Management LP Arcellx, Inc. Transaction History
Brevan Howard Capital Management LP
- $17 Billion
- Q3 2025
A detailed history of Brevan Howard Capital Management LP transactions in Arcellx, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 3,805 shares of ACLX stock, worth $342,373. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,805
Previous 14,436
73.64%
Holding current value
$342,373
Previous $950,000
67.16%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding ACLX
# of Institutions
226Shares Held
51.4MCall Options Held
85.4KPut Options Held
113K-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.35MShares$572 Million0.32% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.65MShares$418 Million12.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.91MShares$352 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$316 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.05MShares$274 Million15.63% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.94B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...